Third Opinion Trial Synopsis
This study wants to find out if a drug called iberdomide is okay and helpful for people with Multiple Myeloma who had a certain treatment before. It's like trying to see if taking iberdomide after another treatment can make the person better.

Trial Summary
The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy. Patients will receive iberdomide treatment beyond 12 months if they continue to derive benefit from the treatment and will continue until progression of disease or unacceptable toxicity. Follow-up will be as per standard of care for a patient on maintenance therapy, and patients will not require additional research samples.